世界中医药
世界中醫藥
세계중의약
WORLD CHINESE MEDICINE
2014年
4期
409-411,414
,共4页
张天宇%张金超%刘妙%吴若菡%张淑静%高誉珊%郑丰杰%许红%李宇航
張天宇%張金超%劉妙%吳若菡%張淑靜%高譽珊%鄭豐傑%許紅%李宇航
장천우%장금초%류묘%오약함%장숙정%고예산%정봉걸%허홍%리우항
慢性阻塞性肺疾病%神经肽%从肠论治
慢性阻塞性肺疾病%神經肽%從腸論治
만성조새성폐질병%신경태%종장론치
Chronic obstructive pulmonary diseases%Neuropeptide%Treatment based on large intestine
目的:观察“通利大肠”对慢性阻塞性肺疾病( COPD)模型大鼠肺组织P物质( SP)、血管活性肠肽( VIP)含量的影响,从神经肽角度探讨COPD“从肠论治”的效应机制。方法:采用熏烟联合气管注射脂多糖复制COPD大鼠模型。50只雄性大Wist-ar鼠随机分为正常组、模型组、治肠组、治肺组、肺肠同治组。正常组和模型组均灌胃给予生理盐水,治肠组、治肺组、肺肠同治组分别用治肠药(生大黄)、治肺药(生石膏、苦杏仁、瓜蒌皮)、肺肠同治药(生大黄、生石膏、苦杏仁、瓜蒌皮)灌胃,连续7d。用免疫组织化学法和酶联免疫吸附法检测肺组织中SP、VIP含量。结果:免疫组化结果显示,与正常组相比,模型组大鼠肺组织SP表达较强,而治肠组、治肺组、肺肠同治组表达较弱;VIP在正常大鼠支气管上皮表达较强,模型组表达明显减弱,各治疗组VIP表达明显增强。酶联免疫吸附法结果显示,与正常组相比,SP在模型组肺组织中含量明显升高,VIP含量明显降低( P<0.01);与模型组相比,治肠组、治肺组、肺肠同治组肺组织SP含量均明显降低,VIP含量明显升高(P<0.01或P<0.05);与治肺组相比,肺肠同治组肺组织SP含量明显降低(P<0.05)。结论:通利大肠或治肺基础上增加通利大肠,可调节COPD模型大鼠肺组织神经肽SP、VIP的含量,这可能是COPD“从肠论治”的效应机制之一。
目的:觀察“通利大腸”對慢性阻塞性肺疾病( COPD)模型大鼠肺組織P物質( SP)、血管活性腸肽( VIP)含量的影響,從神經肽角度探討COPD“從腸論治”的效應機製。方法:採用熏煙聯閤氣管註射脂多糖複製COPD大鼠模型。50隻雄性大Wist-ar鼠隨機分為正常組、模型組、治腸組、治肺組、肺腸同治組。正常組和模型組均灌胃給予生理鹽水,治腸組、治肺組、肺腸同治組分彆用治腸藥(生大黃)、治肺藥(生石膏、苦杏仁、瓜蔞皮)、肺腸同治藥(生大黃、生石膏、苦杏仁、瓜蔞皮)灌胃,連續7d。用免疫組織化學法和酶聯免疫吸附法檢測肺組織中SP、VIP含量。結果:免疫組化結果顯示,與正常組相比,模型組大鼠肺組織SP錶達較彊,而治腸組、治肺組、肺腸同治組錶達較弱;VIP在正常大鼠支氣管上皮錶達較彊,模型組錶達明顯減弱,各治療組VIP錶達明顯增彊。酶聯免疫吸附法結果顯示,與正常組相比,SP在模型組肺組織中含量明顯升高,VIP含量明顯降低( P<0.01);與模型組相比,治腸組、治肺組、肺腸同治組肺組織SP含量均明顯降低,VIP含量明顯升高(P<0.01或P<0.05);與治肺組相比,肺腸同治組肺組織SP含量明顯降低(P<0.05)。結論:通利大腸或治肺基礎上增加通利大腸,可調節COPD模型大鼠肺組織神經肽SP、VIP的含量,這可能是COPD“從腸論治”的效應機製之一。
목적:관찰“통리대장”대만성조새성폐질병( COPD)모형대서폐조직P물질( SP)、혈관활성장태( VIP)함량적영향,종신경태각도탐토COPD“종장론치”적효응궤제。방법:채용훈연연합기관주사지다당복제COPD대서모형。50지웅성대Wist-ar서수궤분위정상조、모형조、치장조、치폐조、폐장동치조。정상조화모형조균관위급여생리염수,치장조、치폐조、폐장동치조분별용치장약(생대황)、치폐약(생석고、고행인、과루피)、폐장동치약(생대황、생석고、고행인、과루피)관위,련속7d。용면역조직화학법화매련면역흡부법검측폐조직중SP、VIP함량。결과:면역조화결과현시,여정상조상비,모형조대서폐조직SP표체교강,이치장조、치폐조、폐장동치조표체교약;VIP재정상대서지기관상피표체교강,모형조표체명현감약,각치료조VIP표체명현증강。매련면역흡부법결과현시,여정상조상비,SP재모형조폐조직중함량명현승고,VIP함량명현강저( P<0.01);여모형조상비,치장조、치폐조、폐장동치조폐조직SP함량균명현강저,VIP함량명현승고(P<0.01혹P<0.05);여치폐조상비,폐장동치조폐조직SP함량명현강저(P<0.05)。결론:통리대장혹치폐기출상증가통리대장,가조절COPD모형대서폐조직신경태SP、VIP적함량,저가능시COPD“종장론치”적효응궤제지일。
Objective:To observe the influence of relaxing large intestine therapy on contents of substance P (SP) and vasoactive intes-tinal peptide (VIP) in rat model with chronic obstructive pulmonary disease (COPD) and explore the effective mechanism of treating COPD based on relaxing the large intestine from the aspect of neuropeptide .Methods:Rats model of COPD were established through in-tratracheal injection of LPS combined with cigarette smoking .Fifty Wistar rats were randomly divided in to normal group , model group , intestine group , lung group and lung-intestine group .The normal group and model group were intragastrically given normal saline solu-tion and other groups were treated with corresponding decoction intragastrically for 7 days.The content of SP and VIP were detected by immunohistochemistry and enzyme-linked immunosorbent assay .Results:Immunohistochemistry results showed that compared with con-trol group , SP in lung tissue of model group was abundantly expressed while in lung group and intestine group and lung -intestine group were weakly expressed .VIP in bronchial epithelium of control group was expressed broadly while model group were lower .After treat-ment , VIP was increased significantly in trial groups .Enzyme-linked immunosorbent assay showed that compared with control group , SP was increased in lung tissue in model group while VIP were decreased significantly ( P<0.01 ) .Compared with model group , SP was lower in lung group, intestine group and lung-intestine group.VIP was increased significantly (P<0.01 or P<0.05).Compared with lung group, SP was reduced significantly in lung-intestine group (P<0.05).Conclusion:The expression of SP and VIP were regulated by the therapy of relaxing the large intestine or relaxing the large intestine on the base of treating lung disease .This may be one of the mechanisms of why treating from intestine is effective on COPD .